EDGAR·FLOW

RELMADA THERAPEUTICS, INC. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 48/100
What the filing says
Relmada Therapeutics announced the appointment of Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer for Urology Uro-Oncology on November 16, 2026. Dr. Jakobsen, formerly Head of Global Clinical Development at Ferring Pharmaceuticals where he led the ADSTILADRIN pivotal program to FDA/EMA/PMDA/Health Canada approvals, will now lead clinical development for Relmada's pipeline including the planned Phase 3 SPECTRUM registrational program for NDV-01. No compensation details, equity grants, or other financial terms are disclosed in this filing.
Why this rating

Leadership hire with strong regulatory pedigree supports upcoming Phase 3 trial execution; meaningful for 18.9M-cap biotech but typical for clinical-stage companies at this stage.

View original filing on SEC.gov ↗ RLMD · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.